Oncology Central

CTLA-4, PD-1 and the Nobel Prize: a patient’s reaction to immunotherapy recognition


This past week, the Nobel Prizes in Physiology or Medicine was awarded to research scientists James Allison (University of Texas MD Anderson Cancer Center, TX, USA) and Tasuku Honjo (Kyoto University, Japan), each of whom has made an enormous contribution to the expanding world of immuno-oncology. Allison “discovered” CTLA-4; or more precisely, realized that blocking it could enable the body’s immune system to fight tumor cells, ultimately developing ipilimumab (Yervoy®) as a treatment for melanoma and, in combination, for several cancers.  Similarly, Honjo discovered the PD-1 protein and launched the development of anti-PD-1 (and related anti-PD-L1) therapies that led to the rapid-fire approvals for pembrolizumab (Keytruda®) and nivolumab (Opdivo®).

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.